65 related articles for article (PubMed ID: 9267073)
1. Elevation of serum soluble interleukin-2 receptor levels in patients with hepatitis C virus infection.
Kawakami Y; Hayashi J; Ueno K; Ohmiya M; Kishihara Y; Yamaji K; Kashiwagi S
Fukuoka Igaku Zasshi; 1997 Jul; 88(7):274-82. PubMed ID: 9267073
[TBL] [Abstract][Full Text] [Related]
2. Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection.
Kawakami Y; Nabeshima S; Furusyo N; Sawayama Y; Hayashi J; Kashiwagi S
Am J Gastroenterol; 2000 Jan; 95(1):227-32. PubMed ID: 10638589
[TBL] [Abstract][Full Text] [Related]
3. Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha.
Grüngreiff K; Reinhold D; Ansorge S
Cytokine; 1999 Dec; 11(12):1076-80. PubMed ID: 10623433
[TBL] [Abstract][Full Text] [Related]
4. The roles of serum IL-18, IL-10, TNF-alpha and sIL-2R in patients with chronic hepatitis C.
Jia HY; Du J; Zhu SH; Ma YJ; Chen HY; Yang BS; Cai HF
Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):378-82. PubMed ID: 14607710
[TBL] [Abstract][Full Text] [Related]
5. Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis.
Elsammak MY; Amin GM; Khalil GM; Ragab WS; Abaza MM
Clin Biochem; 2006 Jun; 39(6):623-9. PubMed ID: 16624274
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
7. Soluble interleukin-2 receptor and interleukin-10 levels in patients with chronic hepatitis B infection.
Tülek N; Saglam SK; Saglam M; Türkyilmaz R; Yildiz M
Hepatogastroenterology; 2000; 47(33):828-31. PubMed ID: 10919040
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus.
Hayashi J; Kishihara Y; Yamaji K; Yoshimura E; Ohmiya M; Tani Y; Ikematsu H; Kashiwagi S
Dig Dis Sci; 1995 Aug; 40(8):1837-41. PubMed ID: 7648988
[TBL] [Abstract][Full Text] [Related]
9. Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases.
Yamaguchi S; Onji M; Ohta Y
Hepatogastroenterology; 1988 Oct; 35(5):245-8. PubMed ID: 3068111
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection.
Migita K; Abiru S; Maeda Y; Daikoku M; Ohata K; Nakamura M; Komori A; Yano K; Yatsuhashi H; Eguchi K; Ishibashi H
Hum Immunol; 2006; 67(1-2):27-32. PubMed ID: 16698422
[TBL] [Abstract][Full Text] [Related]
11. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
12. Effects of alpha-interferon and prednisone on serum-soluble interleukin-2 receptor (sIL-2R) in chronic hepatitis B infection.
Leung NW; Leung JC; Tam JS; Lau JT; Lai KN
Am J Gastroenterol; 1992 Jan; 87(1):113-7. PubMed ID: 1728107
[TBL] [Abstract][Full Text] [Related]
13. [Long-term consequences of co-infection by hepatitis G virus in hepatitis c virus infected kidney transplant patients].
Rostaing L; Izopet J; Arnaud C; Rumeau JL; Duffaut M; Cisterne JM; Durand D
Nephrologie; 1999; 20(3):165-70. PubMed ID: 10418007
[TBL] [Abstract][Full Text] [Related]
14. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis.
Stroffolini T; Almasio PL; Persico M; Bollani S; Benvegnù L; Di Costanzo G; Pastore G; Aghemo A; Stornaiuolo G; Mangia A; Andreone P; Stanzione M; Mazzella G; Saracco G; Del Poggio P; Bruno S;
Am J Gastroenterol; 2008 Aug; 103(8):1966-72. PubMed ID: 18637087
[TBL] [Abstract][Full Text] [Related]
15. [Hepatitis C: epidemiology and therapy--with special reference to long-term prognosis after IFN therapy].
Fujiyama S; Tanaka M
Rinsho Byori; 2000 Jan; 48(1):5-13. PubMed ID: 10756668
[TBL] [Abstract][Full Text] [Related]
16. [Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].
Wu CH; Xu XY; Tian GS; Yu YY
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):390-3. PubMed ID: 16677548
[TBL] [Abstract][Full Text] [Related]
17. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels.
Yamamoto C; Enomoto N; Kurosaki M; Yu SH; Tazawa J; Izumi N; Marumo F; Sato C
Hepatology; 1997 Dec; 26(6):1616-20. PubMed ID: 9398006
[TBL] [Abstract][Full Text] [Related]
20. Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: a predictive marker for IFN therapy.
Akiyoshi F; Sata M; Uchimura Y; Suzuki H; Tanikawa K
Am J Gastroenterol; 1997 Sep; 92(9):1463-6. PubMed ID: 9317063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
